

## AUTHOR INDEX FOR VOLUME 34

## A

- Adamik, R., *see* Moss, J., 279  
 Afar, R., *see* Geertsen, S., 549  
 Andrews, P. R., *see* Manallack, D. T., 863  
 Antkiewicz-Michaluk, L., Guidotti, A., and Krueger, K. E. Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands, 272  
 Arena, J. P., and Kass, R. S. Block of heart potassium channels by clofilium and its tertiary analogs: Relationship between drug structure and type of channel blocked, 60  
 Artymshyn, R. P., *see* Luthin, G. R., 327

## B

- Bach, J.-F., *see* Chatenoud, L., 136  
 Bahouth, S. W., and Malbon, C. C. Subclassification of  $\beta$ -adrenergic receptors of rat fat cells: A re-evaluation, 318  
 Bapat, A. R., *see* Parker, W. B., 485  
 Barbour, K. W., *see* Berger, S. H., 480  
 Barker, J. L., *see* Jones, S. V. P., 421  
 Baudry, M., *see* Terramani, T., 117  
 Bean, A. J., Shepard, P. D., Bunney, B. S., Nestler, E. J., and Roth, R. H. The effects of pertussis toxin on autoreceptor-mediated inhibition of dopamine synthesis in the rat striatum, 715  
 Beart, P. M., *see* Manallack, D. T., 863  
 Beaudet, A., *see* Bochet, P., 436  
 Becker, C., *see* Porzig, H., 172  
 Benishin, C. G., Sorensen, R. G., Brown, W. E., Krueger, B. K., and Blaustein, M. P. Four polypeptide components of green mamba venom selectively block certain potassium channels in rat brain synaptosomes, 152  
 Berg, D. K., *see* McEachern, A. E., 129  
 Berger, F. G., *see* Berger, S. H., 474, 480  
 Berger, S. H., and Berger, F. G. Thymidylate Synthase as a determinant of 5-fluoro-2'-deoxyuridine response in human colonic tumor cell lines, 474  
 Berger, S. H., Barbour, K. W., and Berger, F. G. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line, 480  
 Bernatowicz, M., *see* Muntz, K. H., 444  
 Bero, L. A., Roy, S., and Lee, N. M. Identification of endogenous opioid receptor components in rat brain using a monoclonal antibody, 614  
 Bertolino, M., and Vicini, S. Voltage-dependent block by strychnine of *N*-methyl-D-aspartic acid-activated cationic channels in rat cortical neurons in culture, 98  
 Besselièvre, R., *see* Potier, M.-C., 124  
 Billante, C., *see* Jacqz, E., 215  
 Blaustein, M. P., *see* Benishin, C., 152  
 Bochet, P., Icard-Liepkalns, C., Pasquini, F., Garby-Jaureguiberry, C., Beaudet, A., Roques, B., and Rossier, J. Photoaffinity labeling of opioid  $\delta$  receptors with an iodinated azido-ligand: [ $^{125}$ I] [D-Thr<sup>2</sup>, pN<sup>3</sup>, Phe<sup>4</sup>, Leu<sup>5</sup>]enkephalyl-Thr<sup>6</sup>, 436  
 Bockaert, J., *see* Dumuis, A., 880  
 Bonhaus, D. W., and McNamara, J. O. *N*-methyl-D-aspartate receptor regulation of uncompetitive antagonist binding in rat brain membranes: Kinetic analysis, 250  
 Bonner, T. I., *see* Jones, S. V. P., 421  
 Borden, L. A., and Farb, D. H. Mechanism of  $\gamma$ -aminobutyric acid/benzodiazepine receptor turnover in neuronal cells: Evidence for nonlysosomal degradation, 354  
 Bouhelal, R., *see* Dumuis, A., 880

- Bradfield, C. A., and Poland, A. A competitive binding assay for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and related ligands of the *Ah* receptor, 682  
 Bradfield, C. A., Kende, A. S., and Poland, A. Kinetic and equilibrium studies of *Ah* receptor-ligand binding: Use of [ $^{125}$ I]2-Iodo-7,8-dibromodibenzo-*p*-dioxin, 229  
 Brann, M. R., *see* Jones, S. V. P., 421  
 Broder, S., *see* Hao, Z., 431  
 Brown, E. M., *see* Niznik, H. B., 29  
 Brown, G. B., Gaupp, J. E., and Olsen, R. W. Pyrethroid insecticides: Stereospecific allosteric interaction with the batrachotoxin-A benzozate binding site of mammalian voltage-sensitive sodium channels, 54  
 Brown, W. E., *see* Benishin, C., 152  
 Brunborg, G., *see* Omichinski, J. G., 74  
 Buckley, N. J., *see* Jones, S. V. P., 421  
 Buja, L. M., *see* Muntz, K. H., 444  
 Bunney, B. S., *see* Bean, A. J., 715  
 Burchell, B., *see* Coughtrie, M. W. H., 729  
 Burchell, B., *see* Jackson, M. R., 638  
 Buyukbingol, E., *see* Klopman, G., 852  
 Bylund, D. B., *see* Murphy, T. J., 1

## C

- Caffrey, J. M., and Farach, M. C. A monoclonal antibody specifically modulates dihydropyridine-sensitive calcium current in BC<sub>3</sub>H1 myocytes, 518  
 Calianos, T. A., *see* Muntz, K. H., 444  
 Camerman, A., *see* Loew, G. H., 363  
 Camerman, N., *see* Loew, G. H., 363  
 Carlos, J., Marvizón, G., and Skolnick, P. Anion regulation of [ $^3$ H] strychnine binding to glycine-gated chloride channels is explained by the presence of two anion binding sites, 806  
 Cavero, I., *see* Tahraoui, L., 145  
 Cazenave, P.-A., *see* Chatenoud, L., 136  
 Cha, S., *see* el Kouni, M. H., 104  
 Chapekar, M. S., Knode, M. C., and Glazer, R. I. The epidermal growth factor- and interferon-independent effects of double-stranded RNA in A431 cells, 461  
 Chatenoud, L., Villemain, F., Hoebeke, J., Garbarg, M., Korner, M., Gros, C., Ruat, M., Cazenave, P.-A., Ganellin, C. R., Bach, J.-F., and Schwartz, J.-C. Polyclonal and monoclonal antibodies directed against SK & F 94461, a specific H<sub>1</sub> histamine receptor ligand, 136  
 Chaudhary, A., Thompson, R. H., Rubin, R. P., and Laychock, S. G. Relationship between  $\Delta$ -9-tetrahydrocannabinol-induced arachidonic acid release and secretagogue-evoked phosphoinositide breakdown and Ca<sup>2+</sup> mobilization of exocrine pancreas, 543  
 Chen, C. J., *see* Niznik, H. B., 29  
 Chen, J., *see* Young, W., 239  
 Cheng, Y.-C., *see* Parker, W. B., 485  
 Chi-Rosso, G., *see* Mong, S., 590  
 Chow, K.-C., Macdonald, T., and Ross, W. E. DNA binding by epipodophyllotoxins and *N*-acyl anthracyclines: Implications for mechanism of topoisomerase II inhibition, 467  
 Chu, P. S., *see* Lin, C. M., 200  
 Chu, P. S., *see* Monks, T. J., 15  
 Chu, S. H., *see* el Kouni, M. H., 104  
 Ciaranello, R. D., *see* Stratford, C. A., 527  
 Clark, J. A., Houghten, R., and Pasternak, G. W. Opiate binding in calf thalamic membranes: A selective  $\mu_1$  binding assay, 308  
 Collins, R. M., *see* Jones, S. V. P., 421  
 Compton, R. P., *see* Monahan, J. B., 111  
 Congo, D., *see* Niznik, H. B., 29

- Cooney, D. A., *see* Hao, Z., 431  
Corbin, J. D., *see* Francis, S. H., 506  
Cory, R., *see* Dumuis, A., 880  
Coscia, C. J., *see* Spain, J. W., 23  
Costa, M., *see* Manallack, D. T., 863  
Costa, T., Klinz, F.-J., Vachon, L., and Herz, A. Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes, 744  
Cotgreave, I. A., *see* Rundgren, M., 566  
Coughtrie, M. W. H., Burchell, B., Leakey, J. E. A., and Hume, R. The inadequacy of perinatal glucuronidation: Immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes, 729  
Couraud, F., *see* Marqueze, B., 87  
Cowlen, M. S., and Toews, M. L. Evidence for  $\alpha_1$ -adrenergic receptor internalization in DDT<sub>1</sub> MF-2 cells following exposure to agonists plus protein kinase C activators, 340  
Crankshaw, D., *see* Peterson, F. J., 597  
Crooke, S. T., *see* Mong, S., 590

## D

- Daley, J. W., *see* Nishizawa, Y., 707  
Dekant, W., *see* Schrenk, D., 407  
Dempsy, R. O., *see* Lin, C. M., 200  
Devane, W. A., Dysarz, F. A., III, Johnson, M. R., Melvin, L. S., and Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain, 605  
DeVico, A. L., *see* Hao, Z., 431  
Dimayuga, M. L., *see* Klopman, G., 218  
Dingledine, R., *see* Verdoorn, T. A., 298  
Dodd, R. H., *see* Potier, M.-C., 124  
Ducote, J., *see* Frenkel, G. D., 702  
Duff, H. J., *see* Hill, R. J., 659  
Dumuis, A., Bouhelal, R., Sebben, M., Cory, R., and Bockaert, J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system, 880  
Dybing, E., *see* Omichinski, J. G., 74  
Dysarz, F. A., III, *see* Devane, W. A., 605

## E

- Edmondson, D. E., *see* Tribble, D. L., 413  
Eling, T. E., *see* Hughes, M. F., 186  
el Kouni, M. H., Naguib, F. N. M., Chu, S. H., Cha, S., Ueda, T., Gosselin, G., Imbach, J.-L., Shealy, Y. F., and Otter, B. A. Effect of the N-glycosidic bond conformation and modifications in the pentose moiety on the binding of nucleoside ligands to uridine phosphorylations, 104  
Eng, W.-K., Faucette, L., Johnson, R. K., and Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin, 755  
Everson, R. B., *see* Wang, S.-L., 265  
Evoniuk, G., and Skolnick, P. Picrate and niflumate block anion modulation of radioligand binding to the  $\gamma$ -aminobutyric acid/benzodiazepine receptor complex, 837

## F

- Falvey, D., *see* Frenkel, G. D., 573  
Fanten, U., *see* Lenzen, S., 395  
Farach, M. C., *see* Caffrey, J. M., 518  
Farb, D. H., *see* Borden, L. A., 354  
Farb, D. H., *see* Gyenes, M., 719  
Farber, J. L., *see* Lyle, M. E., 584  
Farrant, M., *see* Gyenes, M., 719  
Faucette, L., *see* Eng, W.-K., 755  
Fisher, J. M., *see* Rabinowitz, M., 401  
Floch, A., *see* Tahraoui, L., 145  
Fogel, E. L., *see* Niznik, H. B., 29

- Forkert, P. G., Mirehouse-Brown, P., Park, S. S., and Gelboin, H. V. Distribution of induction sites of phenobarbital- and 3-methylcholanthrene-inducible cytochromes P-450 in murine liver: Immunohistochemical localization with monoclonal antibodies, 736  
Fournel-Gigleux, S., *see* Jackson, M. R., 638  
Fox, I. H., *see* Lin, B. B., 501  
Francis, S. H., Noblett, B. D., Todd, B. W., Wells, J. N., and Corbin, J. D. Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase, 506  
Frenkel, G. D., and Ducote, J. Methyl mercury stimulates chain elongation by purified HeLa RNA polymerase II, 702  
Frenkel, G. D., and Falvey, D. Evidence for the involvement for sulfhydryl compounds in the inhibition of cellular DNA synthesis by selenite, 573  
Frenking, G., *see* Loew, G. H., 363  
Freytag, S., *see* Lenzen, S., 395  
Fridland, A., *see* Hao, Z., 431

## G

- Ganellin, C. R., *see* Chatenoud, L., 136  
Ganey, P. E., Kauffman, F. C., and Thurman, R. G. Oxygen-dependent hepatotoxicity due to doxorubicin: Role of reducing equivalent supply in perfused rat liver, 695  
Garbarg, M., *see* Chatenoud, L., 136  
Garby-Jaureguiberry, C., *see* Bochet, P., 436  
Gardner, P., *see* Young, W., 239  
Gaupp, J. E., *see* Brown, G. B., 54  
Geertsen, S., Afar, R., Trifaró, J.-M., and Quik, M. Regulation of  $\alpha$ -bungarotoxin sites in chromaffin cells in culture by nicotinic receptor ligands,  $K^+$ , and cAMP, 549  
Gelboin, H. V., *see* Forkert, P. G., 736  
Glazer, R. I., *see* Chapekar, M. S., 461  
Goldman, D. W., *see* Gut, J., 256  
Gommeren, W., *see* Pauwels, P. J., 843  
Gosselin, G., *see* el Kouni, M. H., 104  
Graham, R. M., *see* Muntz, K. H., 444  
Gros, C., *see* Chatenoud, L., 136  
Guidotti, A., *see* Antkiewicz-Michaluk, L., 272  
Gusovsky, F., *see* Nishizawa, Y., 707  
Gut, J., Goldman, D. W., and Trudell, J. R. Conversion of 5-hydrope-roxyeicosatetraenoic acid into leukotriene B<sub>4</sub> by rat hepatocytes: A novel cellular source for leukotriene B<sub>4</sub>, 256  
Gyenes, M., Farrant, M., and Farb, D. H. "Run-Down" of  $\gamma$ -aminobutyric acid<sub>A</sub> receptor function during whole-cell recording: A possible role for phosphorylation, 719

## H

- Halpern, J. L., *see* Moss, J., 279  
Hamblin, M. W., *see* Stratford, C. A., 527  
Hamel, E., *see* Lin, C. M., 200  
Hamik, A., *see* Peroutka, S. J., 537  
Hao, Z., Cooney, D. A., Hartman, N. R., Perno, C. F., Fridland, A., DeVico, A. L., Sarngadharan, M. G., Broder, S., and Johns, D. G. Factors determining activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus *in vitro*, 431  
Harding, D., *see* Jackson, M. R., 638  
Harkness, J., *see* Luthin, G. R., 327  
Harrington, M. A., *see* Peroutka, S. J., 537  
Hartman, N. R., *see* Hao, Z., 431  
Harvison, P. J., *see* Rundgren, M., 566  
Hawrot, E., *see* Wilson, P. T., 643  
Hay, D. W., *see* Mong, S., 590  
Henschler, D., *see* Schrenk, D., 407  
Heroux, J. A., and Roth, J. A. Physical characterization of a monamine-sulfating form of phenol sulfotransferase from human platelets, 194

- Herz, A., *see* Costa, T., 744  
 Hess, M. L., *see* Okabe, E., 388  
 Hewlett, E. L., *see* Moss, J., 279  
 Highet, R. J., *see* Lau, S. S., 829  
 Highet, R. J., *see* Monks, T. J., 15  
 Highet, R. S., *see* Monks, T. J., 492  
 Hill, B. A., *see* Lau, S. S., 829  
 Hill, R. J., Duff, H. J., and Sheldon, R. S. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels, 659  
 Hirning, L. D., *see* Thayer, S. A., 664  
 Hoebeke, J., *see* Chatenoud, L., 136  
 Hoffman, A. J., *see* Peroutka, S. J., 537  
 Hokin, L. E., *see* Reichman, M., 823  
 Holme, J. A., *see* Omichinski, J. G., 74  
 Holtzman, J. L., *see* Peterson, F. J., 597  
 Hom, B. E., *see* Moss, J., 279  
 Homcy, C. J., *see* Muntz, K. H., 444  
 Hood, W. F., *see* Monahan, J. B., 111  
 Houghten, R., *see* Clark, J. A., 308  
 Howlett, A. C., *see* Devane, W. A., 605  
 Hughes, H., *see* Tsokos-Kuhn, J. O., 209  
 Hughes, M. F., Mason, R. P., and Eling, T. E. Prostaglandin hydroperoxidase-dependent oxidation of phenylbutazone: Relationship to inhibition of prostaglandin cyclooxygenase, 186  
 Hulla, J. E., *see* Namkung, M. J., 628  
 Hume, R., *see* Coughtrie, M. W. H., 729  
 Hurley, M. C., *see* Lin, B. B., 501

## I

- Icard-Liepkalns, C., *see* Bochet, P., 436  
 Imbach, J.-L., *see* el Kouni, M. H., 104  
 In, Y., *see* Ishida, T., 377  
 Inoue, M., *see* Ishida, T., 377  
 Insel, P. A., *see* Terman, B. I., 8  
 Iracki, T., *see* Pan, S.-S., 223  
 Ishida, T., In, Y., Ohishi, H., Yamamoto, D., Inoue, M., Tanaka, C., Ueno, Y., Ohmomo, Y., Kanda, N., Tanaka, A., and Tanimoto, T. Structure-activity relationship of aldose reductase inhibitors based on x-ray crystal structures of oxazolecaramate derivatives, 377  
 Ito, H., *see* Okabe, E., 388

## J

- Jackson, M. R., Fournel-Gigleux, S., Harding, D., and Burchell, B. Examination of the substrate specificity of cloned rat kidney phenol UDP-Glucuronyltransferase expressed in COS-7 cells, 638  
 Jacobson, K. A., *see* Stiles, G. L., 724  
 Jacquez, J. A., *see* Thomsen, W. J., 814  
 Jacqz, E., Billante, C., Moysan, F., and Mathieu, H. The non-human primate: A possible model for human genetically determined polymorphisms in oxidative drug metabolism, 215  
 Janassen, P. A. J., *see* Pauwels, P. J., 843  
 Jarvie, K. R., Niznik, H. B., and Seeman, P. Dopamine D<sub>2</sub> receptor binding subunits of *M*<sub>r</sub> ≈ 44,000 and 94,000 in brain: Deglycosylation yields a common unit of *M*<sub>r</sub> ≈ 44,000, 91  
 Johns, D. G., *see* Hao, Z., 431  
 Johnson, G. L., *see* Kelleher, D. J., 452  
 Johnson, M. R., *see* Devane, W. A., 605  
 Johnson, R. K., *see* Eng, W.-K., 755  
 Jones, D. P., *see* Tribble, D. L., 413  
 Jones, S. V. P., Barker, J. L., Buckley, N. J., Bonner, T. I., Collins, R. M., and Brann, M. R. Cloned muscarinic receptor subtypes expressed in A9 L cells differ in their coupling to electrical responses, 421  
 Jones, T. W., Qin, C., Schaeffer, V. H., and Stevens, J. L. Immunohistochemical localization of glutamine transaminase K, a rat kidney cysteine conjugate  $\beta$ -lase, and the relationship to the segment

- specificity of cysteine conjugate nephrotoxicity, 621  
 Juchau, M. R., *see* Namkung, M. J., 628  
 Juchau, M. R., *see* Yang, H.-Y. L., 67  
 Juliano, R. L., *see* Krause, H. J., 286  
 Jung, F., *see* Young, W., 239

## K

- Kanda, N., *see* Ishida, T., 377  
 Kappus, H., *see* Mahmutoglu, I., 578  
 Karlsh, S. J. D., *see* Tal, D. M., 245  
 Kass, R. S., *see* Arena, J. P., 60  
 Kauffman, F. C., *see* Ganey, P. E., 695  
 Keen, M., and Nahorski, S. R. Muscarinic acetylcholine receptors linked to the inhibition of adenylate cyclase activity in membranes from rat striatum and myocardium can be distinguished on the basis of agonist efficacy, 769  
 Kelleher, D. J., and Johnson, G. L. Transducin inhibition of light-dependent rhodopsin phosphorylation: Evidence for  $\beta\gamma$  subunit interaction with rhodopsin, 452  
 Kende, A. S., *see* Bradfield, C. A., 229  
 Kessler, M., *see* Terramani, T., 117  
 Klinz, F.-J., *see* Costa, T., 744  
 Klohs, W. D., and Steinkampf, R. W. The effect of lysomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells, 180  
 Klopman, G., and Buyukbingol, E. An artificial intelligence approach to the study of the structural moieties relevant to drug-receptor interactions in aldose reductase inhibitors, 852  
 Klopman, G., and Dimayuga, M. L. Computer-automated structure evaluation of flavonoids and other structurally related compounds as glyoxalase I enzyme inhibitors, 218  
 Knode, M. C., *see* Chapekar, M. S., 461  
 Korner, M., *see* Chatenoud, L., 136  
 Kragh-Hansen, U. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands, 160  
 Krause, H. J., and Juliano, R. L. Interaction of liposome-incorporated amphotericin B with kidney epithelial cell cultures, 286  
 Krueger, B. K., *see* Benishin, C., 152  
 Krueger, K. E., *see* Antkiewicz-Michaluk, L., 272  
 Kukreja, R. C., *see* Okabe, E., 388  
 Kushner, L., Zukin, S. R., and Zukin, R. S. Characterization of opioid  $\sigma$ , and phencyclidine, receptors in the neuroblastoma-brain hybrid cell line NCB-20, 689

## L

- Lambert, G., *see* Taylor, E. W., 42  
 Lau, S. S., Hill, B. A., Highet, R. J., and Monks, T. J. Sequential oxidation and glutathione addition to 1,4-benzoquinone: Correlation of toxicity with increased glutathione substitution, 829  
 Lau, S. S., *see* Monks, T. J., 15, 492  
 Lawson, J. A., *see* Loew, G. H., 363  
 Laychock, S. G., *see* Chaudhary, A., 543  
 Leakey, J. E. A., *see* Coughtrie, M. W. H., 729  
 Lee, N. M., *see* Bero, L. A., 614  
 Leid, M., Schimerlik, M. I., and Murray, T. F. Characterization of angonist radioligand interactions with porcine atrial A<sub>1</sub> adenosine receptors, 334  
 Lentz, T. L., *see* Wilson, P. T., 643  
 Lenzen, S., Freytag, S., and Fanten, U. Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme, 395  
 Levine, L. Platelet-activating factor stimulates arachidonic acid metabolism in rat liver cells (C-9 cell line) by a receptor-mediated mechanism, 793  
 Levasque, C., *see* Marqueze, B., 87  
 Leysen, J. E., *see* Pauwels, P. J., 843

- Lin, B. B., Hurley, M. C., and Fox, I. H. Regulation of adenosine kinase by adenosine analogs, 501
- Lin, C. M., Singh, S. B., Chu, P. S., Dempcy, R. O., Schmidt, J. M., Pettit, G. R., and Hamel, E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combrestatin: A structure-activity study, 200
- Loew, G. H., Lawson, J. A., Uyeno, E. T., Toll, L., Frenking, G., Polgar, W., Ma, L. Y. Y., Camerman, N., and Camerman, A. Structure-activity studies of morphine fragments. I. 4-Alkyl-4-(*m*-hydroxyphenyl)-piperidines, 363
- Lucier, G. W., *see* Wang, S.-L., 265
- Luthin, G. R., Harkness, J., Artymszyn, R. P., and Wolfe, B. B. Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart, 327
- Lyle, M. E., Nakae, D., Serroni, A., and Farber, J. L. 1,3-(2-chloroethyl)-1-nitrosourea potentiates the toxicity of acetaminophen both in the phenobarbital-induced rat and in hepatocytes cultured from such animals, 584
- Lynch, G., *see* Terramani, T., 117

# M

- Ma, L. Y. Y., *see* Loew, G. H., 363
- Macdonald, T., *see* Chow, K.-C., 467
- Mahmutoglu, I., and Kappus, H. Redox cycling of bleomycin-Fe (III) and DNA degradation by isolated NADH-cytochrome *b<sub>5</sub>* reductase: Involvement of cytochrome *b<sub>5</sub>*, 578
- Malbon, C. C., *see* Bahouth, S. W., 318
- Manallack, D. T., Wong, M. G., Costa, M., Andrews, P. R., and Beart, P. M. Receptor site topographies for phencyclidine-like and  $\sigma$  drugs: Predictions from quantitative conformational, electrostatic potential, and radioreceptor analyses, 863
- Manganiello, V. C., *see* Moss, J., 279
- Marks, G. S., *see* McCluskey, S. A., 80
- Marqueze, B., Martin-Moutot, N., Levêque, C., and Couraud, F. Characterization of the  $\omega$ -conotoxin-binding molecule in rat brain synaptosomes and cultured neurons, 87
- Martin, A. R., *see* Taylor, E. W., 42
- Martin-Moutot, N., *see* Marqueze, B., 87
- Marvizón, G., *see* Carlos, J., 806
- Mason, R. P., *see* Hughes, M. F., 186
- Mason, R. P., *see* Peterson, F. J., 597
- Mathieu, H., *see* Jacqz, E., 215
- Mathias, C. A., *see* Peroutka, S. J., 537
- McCluskey, S. A., Marks, G. S., Whitney, R. A., and Ortiz de Montellano, P. R. Differential inhibition of hepatic ferrochelatase by regioisomers of *N*-butyl-, *N*-pentyl-, *N*-hexyl-, and *N*-isobutylprotoporphyrin IX, 80
- McEachern, A. E., and Berg, D. K. Benzodiazepine interactions with GABA<sub>A</sub> receptors on chick ciliary ganglion neurons, 129
- McGirr, L. G., *see* Rossi, L., 674
- McNamara, J. O., *see* Bonhaus, D. W., 250
- Melvin, L. S., *see* Devane, W. A., 605
- Michel, J., *see* Monahan, J. B., 111
- Miller, R. J., *see* Thayer, S. A., 664
- Miller, R. J., *see* Walker, M. W., 779
- Mirehouse-Brown, P., *see* Forkert, P. G., 736
- Mitchell, J. R., *see* Tsokos-Kuhn, J. O., 209
- Moldéus, P., *see* Rundgren, M., 566
- Monahan, J. B., Hood, W. F., Michel, J., and Compton, R. P. Effects of guanine nucleotides on *N*-methyl-D-aspartate receptor-ligand interactions, 111
- Mondot, S., *see* Tahraoui, L., 145
- Mong, S., Chi-Rosso, G., Hay, D. W., and Crooke, S. T. Subcellular localization of leukotriene D<sub>4</sub> receptors in sheep tracheal smooth muscle, 590
- Monks, T. J., Highet, R. J., Chu, P. S., and Lau, S. S. Synthesis and

- nephrotoxicity of 6-bromo-2,5-dihydroxy-thiophenol, 15
- Monks, T. J., Highet, R. S., and Lau, S. S. 2-bromo-(diglutathion-S-yl)hydroquinone nephrotoxicity: Physiological, biochemical, and electrochemical determinants, 492
- Monks, T. J., *see* Lau, S. S., 829
- Moss, J., Hom, B. E., Hewlett, E. L., Tsai, S.-C., Adamik, R., Halpern, J. L., Price, S. R., and Manganiello, V. C., 279
- Motulsky, H. J., *see* Mueller, H., 347
- Moysan, F., *see* Jacqz, E., 215
- Mueller, H., Motulsky, H. J., and Sklar, L. A. The potency and kinetics of the  $\beta$ -adrenergic receptors on human neutrophils, 347
- Muntz, K. H., Calianos, T. A., Buja, L. M., Willerson, J. T., Bernatowicz, M., Homcy, C. J., and Graham, R. M. Electron microscopic localization of the  $\beta$ -adrenergic receptor using a ferritin-alprenolol probe, 444
- Murphy, T. J., and Bylund, D. B. Oxymetazoline inhibits adenylate cyclase by activation of serotonin-1 receptors in the OK cell, an established renal epithelial cell line, 1
- Murray, T. F., *see* Leid, M., 334

# N

- Naguib, F. N. M., *see* el Kouni, M. H., 104
- Nahorski, S. R., *see* Keen, M., 769
- Nakae, D., *see* Lyle, M. E., 584
- Namkung, M. J., *see* Yang, H.-Y. L., 67
- Namkung, M. J., Yang, H. L., Hulla, J. E., and Juchau, M. R. On the substrate specificity of cytochrome P450III<sub>A1</sub>, 628
- Nelson, D. L., *see* Taylor, E. W., 42
- Nelson, S. D., *see* Omichinski, J. G., 74
- Nelson, S. D., *see* Rundgren, M., 566
- Nen, W., *see* Reichman, M., 823
- Nestler, E. J., *see* Bean, A. J., 715
- Neubig, R. R., *see* Thomsen, W. J., 814
- Nikam, S. S., *see* Taylor, E. W., 42
- Nishizawa, Y., Gusovsky, F., and Daley, J. W. Local anesthetics: Comparison of effects on batrachotoxin-elicited sodium flux and phosphoinositide breakdown in guinea pig cerebral cortical synaptoneurosome, 707
- Niznik, H. B., Fogel, E. L., Chen, C. J., Congo, D., Brown, E. M., and Seeman, P. Dopamine D<sub>2</sub> receptors of the calf parathyroid gland: Identification and characterization, 29
- Niznik, H. B., *see* Jarvie, K. R., 91
- Noblett, B. D., *see* Francis, S. H., 506

# O

- O'Brien, P., *see* Rossi, L., 674
- Odajima, C., *see* Okabe, E., 388
- Ohishi, H., *see* Ishida, T., 377
- Ohmomo, Y., *see* Ishida, T., 377
- Okabe, E., Odajima, C., Taga, R., Kukreja, R. C., Hess, M. L., and Ito, H. The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum, 388
- Olsen, R. W., *see* Brown, G. B., 54
- Omichinski, J. G., Brunborg, G., Holme, J. A., Söderlund, E. J., Nelson, S. D., and Dybing, E. The role of oxidative and conjugative pathways in the activation of 1,2-dibromo-3-chloropropane to DNA-damaging products in rat testicular cells, 74
- Ortiz de Montellano, P. R., *see* McCluskey, S. A., 80
- Otter, B. A., *see* el Kouni, M. H., 104

# P

- Pan, S.-S., and Iracki, T. Metabolites and DNA adduct formation from flavoenzyme-activated porfomycin, 223
- Park, S. S., *see* Forkert, P. G., 736
- Parker, W. B., Bapat, A. R., Shen, J.-X., Townsend, A. J., and Cheng, Y.-C. Interaction of 2-halogenated dAPT analogs (F, Cl, and Br)

- with human DNA polymerases, DNA primase, and ribonucleotide reductase, 485
- Parsons, W. J., Ramkumar, V., and Stiles, G. L. Isobutylmethylxanthine stimulates adenylate cyclase by blocking the inhibitory regulatory protein, G<sub>i</sub>, 37
- Pasquini, F., *see* Bochet, P., 436
- Pasternak, G. W., *see* Clark, J. A., 308
- Pauwels, P. J., Gommeren, W., Van Lommen, G., Janssen, P. A. J., and Leysen, J. E. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various  $\beta$ -adrenergic blockers, 843
- Perno, C. F., *see* Hao, Z., 431
- Peroutka, S. J., Hamik, A., Harrington, M. A., Hoffman, A. J., Mathis, C. A., Pierce, P. A., and Wang, S. S.-H. (R)-(-)-[<sup>77</sup>Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes, 537
- Peterson, F. J., Holtzman, J. L., Crankshaw, D., and Mason R. P. Two sites of azo reduction in the monooxygenase system, 597
- Petta, D. E., *see* Spain, J. W., 23
- Pettit, G. R., *see* Lin, C. M., 200
- Pierce, P. A., *see* Peroutka, S. J., 537
- Poland, A., *see* Bradfield, C. A., 229
- Poland, A. A., *see* Bradfield, C. A., 682
- Polgar, W., *see* Loew, G. H., 363
- Porubek, D. J., *see* Rundgren, M., 566
- Porzig, H., and Becker, C. Potential-dependant allosteric modulation of 1,4-dihydropyridine binding by D-(*cis*)-diltiazem and (+)-verapamil in living cardiac cells, 172
- Potier, M.-C., Prado de Carvalho, L., Dodd, R. H., Besselievre, R., and Rossier, J. *In vivo* binding of  $\beta$ -carbolines in mice: Regional differences and correlation of occupancy to pharmacological effects, 124
- Prado de Carvalho, L., *see* Potier, M.-C., 124
- Presky, D. H., and Schonbrunn, A. Iodination of [Tyr<sup>11</sup>] somatostatin yields a super high affinity ligand for somatostatin receptors in GH<sub>4</sub>C<sub>1</sub> cells, 651
- Price, S. R., *see* Moss, J., 279

## Q

- Qin, C., *see* Jones, T. W., 621
- Quandt, F. N. Modification of slow inactivation of single sodium channels by phenytoin in neuroblastoma cells, 557
- Quik, M., *see* Geertsens, S., 549

## R

- Rabinowitz, M., and Fisher, J. M. Evidence for a copper: S-(methylthio)-L-homocysteine complex as a glutamine antagonist of cytidine triphosphate synthesis in L1210 murine leukemia cells, 401
- Ramkumar, V., and Stiles, G. L. The new positive inotrope sulmazole inhibits the function of guanine nucleotide regulatory proteins by affecting GTP turnover, 761
- Ramkumar, V., *see* Parsons, W. J., 37
- receptor, 643
- Reichman, M., Nen, W., and Hokin, L. E.  $\Delta^9$ -tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices, 823
- Roques, B., *see* Bochet, P., 436
- Ross, W. E., *see* Chow, K.-C., 467
- Rossi, L., McGirr, L. G., Silva, J., and O'Brien, P. The metabolism of N-acetyl-3,5-dimethyl-p-benzoquinone imine in isolated hepatocytes involves N-deacetylation, 674
- Rossier, J., *see* Bochet, P., 436
- Rossier, J., *see* Potier, M.-C., 124
- Roth, J. A., *see* Heroux, J. A., 194
- Roth, R. H., *see* Bean, A. J., 715
- Roy, S., *see* Bero, L. A., 614
- Ruat, M., *see* Chatenoud, L., 136
- Rubin, R. P., *see* Chaudhary, A., 543

- Rundgren, M., Porubek, D. J., Harvison, P. J., Cotgreave, I. A., Moldeus, P., and Nelson, S. D. Comparative cytotoxic effects of N-acetyl-p-benzoquinone imine and two dimethylated analogues, 566

## S

- Sarnagadharan, M. G., *see* Hao, Z., 431
- Schaeffer, V. H., *see* Jones, T. W., 621
- Schimerlik, M. I., *see* Leid, M., 334
- Schmalzing, G. The role of a transmembrane pH gradient in uptake and release of imipramine and haloperidol in synaptosomes, 888
- Schmidt, J. M., *see* Lin, C. M., 200
- Schonbrunn, A., *see* Presky, D. H., 651
- Schrenk, D., Dekant, W., and Henschler, D. Metabolism and excretion of S-conjugates derived from hexachlorodibutadiene in the isolated perfused rat kidney, 407
- Schwartz, J.-C., *see* Chatenoud, L., 136
- Sebben, M., *see* Dumuis, A., 880
- Seeman, P., *see* Jarvie, K. R., 91
- Seeman, P., *see* Niznik, H. B., 29
- Serroni, A., *see* Lyle, M. E., 584
- Shealy, Y. F., *see* el Kouni, M. H., 104
- Sheldon, R. S., *see* Hill, R. J., 659
- Shen, J.-X., *see* Parker, W. B., 485
- Shepard, P. D., *see* Bean, A. J., 715
- Shiverick, K. T., *see* Wang, S.-L., 265
- Silva, J., *see* Rossi, L., 674
- Singh, S. H., *see* Lin, C. M., 200
- Sklar, L. A., *see* Mueller, H., 347
- Skolnick, P., *see* Carlos, J., 806
- Skolnick, P., *see* Evoniuk, G., 837
- Smith, C. V., *see* Tsokos-Kuhn, J. O., 209
- Snyder, S. H., *see* Verma, A., 800
- Søderlund, E. J., *see* Omichinski, J. G., 74
- Sorensen, R. G., *see* Benishin, C., 152
- Spain, J. W., Petta, D. E., and Coscia, C. J. Binding kinetics of  $\delta$  opioid receptors differ for microsomal and synaptic sites, 23
- Steinkampf, R. W., *see* Klohs, W. D., 180
- Sternglanz, R., *see* Eng, W.-K., 755
- Stevens, J. L., *see* Jones, T. W., 621
- Stiles, G. L., and Jacobson, K. A. High affinity acylating antagonists for the A<sub>1</sub> adenosine receptor: Identification of binding subunit, 724
- Stiles, G. L., *see* Parsons, W. J., 37
- Stiles, G. L., *see* Ramkumar, V., 761
- Stratford, C. A., Tan, G. L., Hamblin, M. W., and Ciaranello, R. D. Differential inactivation and G protein reconstruction of subtypes of [<sup>3</sup>H]5-hydroxytryptamine binding sites in brain, 527
- Sunahara, G. I., *see* Wang, S.-L., 265

## T

- Taga, R., *see* Okabe, E., 388
- Tahraoui, L., Floch, A., Mondot, S., and Caverio, I. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: Counterparts of platelet-activating factor receptors mediating platelets aggregation, 145
- Tal, D. M., and Karlish, S. J. D. Do canrenone and 6,7-dihydroxylated derivatives compete with ouabain at the same site on Na,K-ATPase?, 245
- Tan, G. L., *see* Stratford, C. A., 527
- Tanaka, A., *see* Ishida, T., 377
- Tanaka, C., *see* Ishida, T., 377
- Tanimoto, T., *see* Ishida, T., 377
- Taylor, E. W., Nikam, S. S., Lambert, G., Martin, A. R., and Nelson, D. L. Molecular determinants of recognition of RU 24969 analogs at central 5-hydroxytryptamine recognition sites: Use of a bilinear function and substituent volumes to describe steric fit, 42
- Terman, B. I., and Insel, P. A. Use of 1-deoxymannojirimycin to show

- that complex oligosaccharides regulate cellular distribution of the  $\alpha_1$ -adrenergic receptor glycoprotein in BC<sub>3</sub>H<sub>1</sub> muscle cells, 8
- Terramani, T., Kessler, M., Lynch, G., and Baudry, M. Effects of thiol-reagents on [<sup>3</sup>H]  $\alpha$ -amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to rat telencephalic membranes, 117
- Thayer, S. A., Hirning, L. D., and Miller, R. J. The role of caffeine-sensitive calcium stores in the regulation of the intracellular free calcium concentration in rat sympathetic neurons *in vitro*, 664
- Thompson, R. H., *see* Chaudhary, A., 543
- Thomsen, W. J., Jacquez, J. A., and Neubig, R. R. Inhibition of adenylate cyclase is mediated by the high affinity conformation of the  $\alpha_2$ -adrenergic receptor, 814
- Thurman, R. G., *see* Ganey, P. E., 695
- Todd, B. W., *see* Francis, S. H., 506
- Toews, M. L., *see* Cowlen, M. S., 340
- Toll, L., *see* Loew, G. H., 363
- Townsend, A. J., *see* Parker, W. B., 485
- Tribble, D. L., Jones, D. P., and Edmondson, D. E. Effect of hypoxia on *tert*-butylhydroperoxide-induced oxidative injury in hepatocytes, 413
- Trifaró, J.-M., *see* Geertsens, S., 549
- Trudell, J. R., *see* Gut, J., 256
- Tsai, S.-C., *see* Moss, J., 279
- Tsokos-Kuhn, J. O., Smith, C. V., Hughes, H., and Mitchell, J. R. Liver membrane calcium transport in diquat-induced oxidative stress *in vivo*, 209

## U

- Ueda, T., *see* el Kouni, M. H., 104
- Ueno, Y., *see* Ishida, T., 377
- Uyeno, E. T., *see* Loew, G. H., 363

## V

- Vachon, L., *see* Costa, T., 744
- Van Lommen, G., *see* Pauwels, P. J., 843
- Verdoorn, T. A., and Dingledine, R. Excitatory amino acid receptors expressed in *Xenopus* oocytes: Agonist pharmacology, 298
- Verma, A., and Snyder, S. H. Characterization of porphyrin interactions with peripheral type benzodiazepine receptors, 800

- Vicini, S., *see* Bertolino, M., 98
- Villemain, F., *see* Chatenoud, L., 136

## W

- Walker, M. W., and Miller, R. J. <sup>125</sup>I-neuropeptide Y and <sup>125</sup>I-peptide YY bind to multiple receptor sites in rat brain, 779
- Wang, S.-L., Lucier, G. W., Everson, R. B., Sunahara, G. I., and Shiverick, K. T. Smoking-related alterations in epidermal growth factor and insulin receptors in human placenta, 265
- Wang, S. S.-H., *see* Peroutka, S. J., 537
- Wells, J. N., *see* Francis, S. H., 506
- White, M. M. Forskolin alters acetylcholine receptor gating by a mechanism independent of adenylate cyclase activation, 427
- Whitney, R. A., *see* McCluskey, S. A., 80
- Willerson, J. T., *see* Muntz, K. H., 444
- Wilson, P. T., Hawrot, E., and Lentz, T. L. Distribution of  $\alpha$ -bungarotoxin binding sites over residues binding sites over residues 173-204 of the  $\alpha$  subunit of the acetylcholine
- Wolfe, B. B., *see* Luthin, G. R., 327
- Wong, M. G., *see* Manallack, D. T., 863

## X

x

## Y

- Yamamoto, D., *see* Ishida, T., 377
- Yang, H. L., *see* Namkung, M. J., 628
- Yang, H.-Y. L., Namkung, M. J., and Juchau, M. R. Cytochrome P-450-dependent biotransformation of a series of phenoxazone ethers in the rat conceptus during early organogenesis: Evidence for multiple P-450 isoenzymes, 67
- Young, W., Chen, J., Jung, F., and Gardner, P. Dihydropyridine Bay-K 8644 activates T lymphocyte calcium-permeable channels, 239

## Z

- Zukin, R. S., *see* Kushner, L., 689
- Zukin, S. R., *see* Kushner, L., 689

# SUBJECT INDEX FOR VOLUME 34

## A

- A431 cells, poly(I)-poly(C), effects, double-stranded RNA, 461
- Acetaminophen, toxicity, 1,3-(2-chloroethyl)-1-nitrosourea, hepatocytes (rat), 584
- N*-Acetyl-3,5-dimethyl-*p*-benzoquinone imine, metabolism in hepatocytes, *N*-deacetylation (rat), 674
- Acetylcholine
  - cloned muscarinic receptor subtypes, coupling, electrical responses, 421
  - receptor gating, forskolin, adenylate cyclase activation, 427
- N*-Acetyl-*p*-benzoquinone imine, comparative cytotoxic effects, dimethylated analogues, 566
- Acquired immune deficiency syndrome, HIV suppression, 2',3'-dideoxynucleosides, 431
- N*-Acyl anthracyclines, epipodophyllotoxins and, DNA binding, topoisomerase II inhibition, 467
- Adenosine analogs, regulation of adenosine kinase, 501
- Adenosine monophosphate, cyclic
  - dopamine D<sub>1</sub> receptors, parathyroid gland (calf), 29
  - regulation of  $\alpha$ -bungarotoxin sites, nicotinic receptor ligands, chromaffin cells, 549
  - subclassification of  $\beta$ -adrenergic receptors, fat cells (rat), 318
- Adenylate cyclase
  - acetylcholine receptor gating, forskolin, 427
  - enhanced sensitivity to bradykinin, pertussis toxin-treated fibroblasts, 279
  - inhibition of, high affinity conformation,  $\alpha$ -2 adrenoceptor, 814
  - inhibition of G protein function, sulmazole, GTP turnover (rat), 761
  - loose coupling of opioid receptors, G proteins, NG108-15 cell membranes, 744
  - muscarinic acetylcholine receptors, distinction of, agonist efficacy (rat), 769
  - positive coupling, 5-HT<sub>4</sub> receptors, central nervous system (guinea pig), 880
  - stimulation by isobutylmethylxanthine, blockade, inhibitory regulatory protein G<sub>i</sub> (rat), 37
- ADP-ribosylation, enhanced sensitivity to bradykinin, pertussis toxin-treated fibroblasts, 279
- $\beta$ -Adrenergic blockers, compared to nebivolol, receptor binding profile, 843
- Adrenoceptors
  - $\alpha$ -1
    - distribution regulation, BC<sub>3</sub>H<sub>1</sub> muscle cells, 8
    - internalization in DDT<sub>1</sub> MF-2 cells (hamster), 340
  - $\alpha$ -2
    - high affinity conformation, adenylate cyclase inhibition, 814
    - inhibition of adenylate cyclase, serotonin-1 receptors (opposum), 1
  - $\beta$ 
    - localization, ferritin-alprenolol probe, 444
    - potency and kinetics, neutrophils (human), 347
    - subclassification, fat cells (rat), 318
- Albumin, relationships between drug-binding sites, 160
- A9 L cells, cloned muscarinic receptor subtypes, coupling, electrical responses, 421
- Aldose reductase inhibitors
  - artificial intelligence approach, structural moieties, drug-receptor interactions, 852
  - structure-activity relationship, 377
- 4-Alkyl-4-(*m*-hydroxy-phenyl)-piperidines, structure-activity studies, 363
- N*-Alkylporphyrin, inhibition of hepatic ferrochelatase (rat), 80

- Alloxan, inhibition of glucokinase, sugar-binding site of enzyme (mouse), 395
- Alprenolol, -ferritin probe, localization,  $\beta$ -adrenergic receptor, 444
- 4-Amino-2,6-dimethylphenol, *N*-acetyl-3,5-dimethyl-*p*-benzoquinone metabolism, *N*-deacetylation, hepatocytes (rat), 674
- Amino acids
  - excitatory, agonist pharmacology, oocytes (*Xenopus*), 298
  - thiol-reagents, AMPA binding, synaptic membranes (rat), 117
- $\gamma$ -Aminobutyric acid
  - benzodiazepine receptor complex, blockade of anion modulation, picrate and niflumate (rat), 837
- GABA<sub>A</sub>, benzodiazepine interactions, ciliary ganglion nerves (chick), 129
- receptor function during whole-cell recording, phosphorylation (chick), 719
- receptor turnover, neuronal cells (chick), 354
- $\alpha$ -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid, binding to synaptic membranes, effects, thiol-reagents (rat), 117
- AMPA, *see*  $\alpha$ -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid
- Amphotericin B, liposome-incorporated, interactions, kidney epithelial cells, 286
- Analgesics, cannabinoid receptors, brain (rat), 605
- Anesthetics
  - forskolin, acetylcholine receptor gating, 427
  - local, sodium flux, cerebral cortical synaptoneurosomes (guinea pig), 707
- Anions
  - blockade of modulation, picrate and niflumate, GABA/benzodiazepine receptor complex (rat), 837
  - regulation of strychnine binding, glycine-gated chloride channels, 806
- Anthracycline, retention and activity, lysosomotropic agents, multiple drug-resistant cells, 180
- Antiarrhythmic drugs
  - block of heart potassium channels, clofilium (guinea pig), 60
  - stereospecific binding, cardiac sodium channels (rat), 659
- Antihypertensive agents, nebivolol, receptor binding profile, 843
- Antimitotic drugs, natural and synthetic analogs of combretastatin, interactions, tubulin, 200
- Arachidonic acid
  - increase in levels, tetrahydrocannabinol, cerebral cortex slices (guinea pig), 823
  - stimulation of metabolism in liver cells, platelet-activating factor (rat), 793
  - tetrahydrocannabinol-induced, calcium mobilization, exocrine pancreas (rat), 543
- Assays
  - batrachotoxinin-A benzoate binding site, pyrethroid insecticides, sodium channels (rat), 54
  - $\mu_1$  binding, 308
  - competitive binding, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, *Ah* receptor, 682
- Autoreceptors, inhibition of dopamine synthesis, pertussis toxin effects, striatum (rat), 715
- Azido-ligand, photoaffinity labeling, opioid  $\delta$  receptors, 436
- Azo compounds, two sites of reduction, monooxygenase system (rat), 597

## B

- Batrachotoxin-elicited sodium flux, local anesthetics, cerebral cortical synaptoneurosomes (guinea pig), 707

- Batrachotoxinin-A, benzoate binding site, pyrethroid insecticides, sodium channels (rat), 54
- Bay K 8644, activation, T cell calcium channels, 239
- Benzodiazepine  
interactions with GABA<sub>A</sub> receptors, ciliary ganglion nerves (chick), 129  
*in vivo* binding,  $\beta$ -carbolines (mouse), 124  
peripheral-type ligands, mitochondrial density (rat), 272
- 1,4-Benzoquinone, sequential oxidation and glutathione addition, toxicity correlation, 829
- Bleomycin-Fe(III), redox cycling, DNA degradation, NADH-cytochrome *b<sub>5</sub>* reductase (rat), 578
- Bradykinin, mechanism of enhanced sensitivity, pertussis toxin-treated fibroblasts, 279
- Brain  
antibodies to muscarinic receptors (rat), 327  
cannabinoid receptors (rat), 605  
cortical neurons, strychnine blockade, NMDA-activated channels (rat), 98  
dopamine D<sub>2</sub> receptor binding units, deglycosylation (dog, pig), 91  
endogenous opioid receptor components, monoclonal antibodies (rat), 614  
membranes, NMDA receptor regulation, uncompetitive antagonist binding (rat), 250  
multiple receptor site binding, monoiodinated neuropeptide Y and peptide YY (rat), 779  
neuronal cells, GABA<sub>A</sub> receptor turnover (chick), 354  
novel serotonin binding site, 4-bromo-2,5-dimethoxyamphetamine (rat), 537  
serotonin binding sites, G protein reconstitution (bovine), 527  
synaptosomes  
characterization,  $\omega$ -conotoxin-binding molecule (rat), 87  
dendrotoxin blockade, potassium channels (rat), 152  
thiol-reagents, AMPA binding, synaptic membranes (rat), 117
- 6-Bromo-2,5-dihydroxy-thiophenol, synthesis and nephrotoxicity (rats), 15
- 4-Bromo-2,5-dimethoxyamphetamine, labeling of novel serotonin binding site, brain membranes (rat), 537
- 2-Bromo-(diglutathion-*S*-yl)hydroquinone, nephrotoxicity (rat), 492
- $\alpha$ -Bungarotoxin  
distribution of binding sites, acetylcholine receptor (*Torpedo*), 643  
regulation of sites in chromaffin cells, nicotinic receptor ligands, potassium and cAMP, 549
- tert*-Butylhydroperoxide-induced oxidative injury, hypoxia effect, hepatocytes (rat), 413

## C

- Caffeine-sensitive calcium stores, regulation, sympathetic neurons (rat), 664
- Calcium  
caffeine-sensitive stores of, regulation, sympathetic neurons (rat), 664  
mobilization of exocrine pancreas, arachidonic acid release, tetrahydrocannabinol (rat), 543  
permeability, oxygen free radicals, cardiac sarcoplasmic reticulum (dog), 388  
transport in liver membrane, diquat-induced oxidative stress (rat), 209
- Calcium channels  
characterization of  $\omega$ -conotoxin-binding molecule, brain synaptosomes, neurons (rat), 87  
dihydropyridine-sensitive, monoclonal antibody, BC<sub>3</sub>H1 myocytes, 518  
diltiazem and verapamil, 1,4-dihydropyridine binding, cardiac cells (rat), 172  
T cells, activation, Bay K 8644, 239
- Camptothecin, cytotoxic effects, necessity of DNA topoisomerase I, 755

- Canrenone, 6,7-dihydroxylated derivatives and, ouabain competition, Na/K-ATPase, 245
- $\beta$ -Carbolines, *in vivo* binding (mouse), 124
- Central nervous system, non-classical serotonin receptors, positive coupling, adenylate cyclase (guinea pig), 880
- Cerebral cortex, increase in arachidonic acid levels, tetrahydrocannabinol (guinea pig), 823
- Chemotherapy, computer-automated structure evaluation, flavonoids, 210
- Chloride channels, glycine-gated, anion regulation, strychnine binding, 806
- 1,3-(2-Chloroethyl)-1-nitrosourea, toxicity of acetaminophen, phenobarbital-induced, hepatocytes (rat), 584
- Cholera toxin, enhanced sensitivity to bradykinin, pertussis toxin-treated fibroblasts, 279
- Chromaffin cells, regulation of  $\alpha$ -bungarotoxin sites, nicotinic receptor ligands, potassium and cAMP, 549
- Chromome, computer-automated structure evaluation, flavonoids, 210
- Cigarette smoking-related placental alterations, epidermal growth factor, insulin receptors (human), 265
- CL 218,872, *in vivo* binding,  $\beta$ -carbolines (mouse), 124
- Clofilium, block of heart potassium channels (guinea pig), 60
- Colchicine analogs, combretastatin analogs, interactions, tubulin, 200
- Collicular neurons, non-classical serotonin receptors, positive coupling, adenylate cyclase (guinea pig), 880
- Colonic tumor, thymidylate synthase, determinant, 5-fluoro-2'-deoxyuridine response (human), 474, 480
- Combretastatin, natural and synthetic analogs of, interactions, tubulin, 200
- $\omega$ -Conotoxin-binding molecule, characterization, brain synaptosomes (rat), 87
- Copper, *S*-(Methylthio)-L-homocysteine complex, cytidine triphosphate synthesis, L1210 cells (mouse), 401
- COS-7 cells, phenol UDP-glucuronosyltransferase, substrate specificity (rat, monkey), 638
- Coumarin, computer-automated structure evaluation, flavonoids, 210
- Cyclic AMP, *see* Adenosine monophosphate, cyclic
- Cysteine conjugate  $\beta$ -lyase, kidney localization (rat), 621
- Cytidine triphosphate, synthesis in L1210 cells, copper:*S*-(methylthio)-L-homocysteine complex (mouse), 401
- Cytochrome *b<sub>5</sub>* reductase, redox cycling of bleomycin-Fe(III), DNA degradation (rat), 578
- Cytochrome P-450  
biotransformation of phenoxazone ethers, conceptus (rat), 67  
phenobarbital- and 3-methylcholanthrene-inducible, distribution and induction (mouse), 736  
two sites of azo reduction, monooxygenase system (rat), 597
- Cytochrome P-450III<sub>A1</sub>, substrate specificity (rat), 628

## D

- DDT, MF-2 cells,  $\alpha_1$ -adrenergic receptor internalization (hamster), 340
- Debrisoquine, genetically determined polymorphisms, non-human primate as model, oxidative drug metabolism, 215
- Dendrotoxins, potassium channel blockade, brain synaptosomes (rat), 152
- Deoxyadenosine analogs, 2-halogenated, mechanism of action, 485
- 1-Deoxymannojirimycin, adrenergic receptor distribution regulation, BC<sub>3</sub>H<sub>1</sub> muscle cells, 8
- 1,2-Dibromo-3-chloropropane, role of oxidative and conjugative pathways, DNA-damaging products, testicular cells (rat), 74
- 2',3'-Dideoxynucleosides, HIV suppression, 431
- 1,4-Dihydropyridine  
Bay K 8644, activation, T cell calcium channels, 239  
binding by diltiazem and verapamil, living cardiac cells (rat), 172
- Dihydropyridine analogues, inhibition of hepatic ferrochelatase, *N*-alkylporphyrin regioisomers (rat), 80
- Diltiazem, 1,4-dihydropyridine binding, allosteric modulation, cardiac cells (rat), 172



- 3,5-Dimethylacetaminophen, *N*-acetyl-3,5-dimethyl-*p*-benzoquinone imine metabolism, *N*-deacetylation, hepatocytes (rat), 674
- Diquat, -induced oxidative stress, calcium transport, liver membrane (rat), 209
- Dithiols, inhibition of glucokinase by alloxan, sugar-binding site of enzyme (mouse), 395
- DNA  
 adduct formation, flavoenzyme-activated porfirimycin, 223  
 binding by epipodophyllotoxins, *N*-acyl anthracyclines, topoisomerase II inhibition, 467  
 damage, 1,2-dibromo-3-chloropropane activation, testicular cells (rat), 74  
 degradation, redox cycling, bleomycin-Fe(III) (rat), 578  
 inhibition of synthesis by selenite, sulfhydryl compounds, 573  
 necessity of topoisomerase I, cytotoxic effects, camptothecin, 755
- DNA polymerase, 2-halogenated deoxyadenosine analogs, mechanism of action, 485
- Dopamine  
 receptors, *see* Receptors  
 synthesis in striatum, pertussis toxin, autoreceptor-mediated inhibition (rat), 715
- Dopamine sulfate, characterization of phenol sulfotransferase, monoamine-sulfating form, 194
- Doxorubicin  
 lysosomotropic agents, anthracycline retention, multiple drug-resistant cells, 180  
 oxygen-dependent hepatotoxicity (rat), 695
- E**
- Embryo, cytochrome P-450s, biotransformation, phenoxazone ethers (rat), 67
- Enkephalin,  $\mu_1$  opiate binding assay, 308
- Epidermal growth factor  
 insulin receptors and, smoking-related alterations, placenta (human), 265  
 poly(I)-poly(C), effects, double-stranded RNA in A431 cells, 461
- Epipodophyllotoxins, *N*-acyl anthracyclines and, DNA binding, topoisomerase II inhibition, 467
- Epithelial cells, kidney, interactions, liposome-incorporated amphotericin B, 286
- Erythrocytes, localization of  $\beta$ -adrenergic receptor, ferritin-alprenolol probe, 444
- F**
- Fat cells, subclassification,  $\beta$ -adrenergic receptors (rat), 318
- Ferritin-alprenolol probe, localization,  $\beta$ -adrenergic receptor, 444
- Ferrochelataase, *N*-alkylporphyrin inhibition (rat), 80
- Fetus, inadequacy of perinatal glucuronidation, UDP-glucuronosyltransferase isozymes (rat, human), 729
- Fibroblasts, pertussis toxin-treated, enhanced sensitivity, bradykinin, 279
- Flavoenzyme, -activated porfirimycin, metabolites, DNA adduct formation, 223
- Flavonoids, computer-automated structure evaluation, 218
- 5-Fluoro-2'-deoxyuridine  
 reduced response in colonic tumor, thymidylate synthase variation (human), 480  
 response in colonic cell lines, thymidylate synthase (human), 474
- Forskolin, acetylcholine receptor gating, independent mechanism, adenylate cyclase activation, 427
- Fura-2, caffeine-sensitive calcium stores, regulation, sympathetic neurons (rat), 664
- G**
- Ganglion nerves, ciliary, benzodiazepine interactions, GABA<sub>A</sub> receptors (chick), 129
- Glucokinase, inhibition by alloxan, sugar-binding site of enzyme (mouse), 395
- Glucuronidation, perinatal, inadequacy of (rat, human), 729
- Glutamate, NMDA receptor-ligand interactions, effects, guanine nucleotides, 111
- Glutamine, copper:*S*-(methylthio)-L-homocysteine complex, cytidine triphosphate synthesis, L1210 cells (mouse), 401
- Glutamine transaminase K, immunohistochemical localization, segment specificity, cysteine conjugate nephrotoxicity (rat), 621
- Glutathione  
*N*-acetyl-3,5-dimethyl-*p*-benzoquinone imine metabolism, *N*-deacetylation (rat), 674  
 addition to 1,4-benzoquinone, sequential oxidation, toxicity correlation, 829  
 metabolism and excretion of *S*-conjugates, hexachlorobutadiene, kidney (rat), 407
- Glutathione *S*-transferase, 1,2-dibromo-3-chloropropane activation, DNA-damaging products, testicular cells (rat), 74
- Glycine-gated chloride channels, anion regulation, strychnine binding, 806
- Glycoproteins, adrenergic receptor distribution regulation, BC<sub>3</sub>H<sub>1</sub> muscle cells, 8
- Glyoxalase I, inhibitors, flavonoids, computer analysis, 210
- Golgi apparatus, lysosomotropic agents, anthracycline retention, multiple drug-resistant cells, 180
- G proteins  
 adenylate cyclase inhibition, high affinity conformation,  $\alpha$ -2 adrenoceptors, 814  
 adenylate cyclase stimulation, isobutylmethylxanthine (rat), 37  
 cannabinoid receptors, brain (rat), 605  
 enhanced sensitivity to bradykinin, pertussis toxin-treated fibroblasts, 279  
 inhibition of function, sulmazole, GTP turnover (rat), 761  
 reconstitution, serotonin binding sites, brain (bovine), 527  
 tight coupling of opioid receptors, NG108-15 cell membranes, 744
- Guanine nucleotide binding proteins, *see* G proteins
- Guanine nucleotides, *N*-methyl-D-aspartate receptor-ligand interactions, 111
- Guanosine monophosphate, cyclic, relaxation of vascular and tracheal smooth muscle, protein kinase, 506
- Guanosine triphosphate, inhibition of G protein function, sulmazole (rat), 761
- H**
- Haloperidol, uptake and release, transmembrane pH gradient, synaptosomes, 888
- Heart  
 agonist radioligand interactions, atrial A<sub>1</sub> adenosine receptors (pig), 334  
 antibodies to muscarinic receptors (rat), 327  
 block of potassium channels, clofilium (guinea pig), 60  
 1,4-dihydropyridine binding, allosteric modulation, calcium antagonists (rat), 172  
 sarcoplasmic reticulum, oxygen free radicals, calcium permeability (dog), 388
- HeLa cells, RNA polymerase II, methyl mercury, chain elongation, 702
- Hepatocytes  
*N*-acetyl-3,5-dimethyl-*p*-benzoquinone imine metabolism, *N*-deacetylation (rat), 674  
 1,3-(2-chloroethyl)-1-nitrosourea, toxicity, acetaminophen (rat), 584  
 comparative cytotoxic effects, dimethylated analogues, *N*-acetyl-*p*-benzoquinone, 566  
 conversion of 5-hydroperoxyeicosatetraenoic acid, leukotriene B<sub>4</sub> (rat), 256  
 effect of hypoxia, *tert*-butylhydroperoxide-induced oxidative injury (rat), 413
- Hepatotoxicity, oxygen-dependent, doxorubicin (rat), 695
- Hexachlorobutadiene, excretion of *S*-conjugates, kidney (rat), 407
- Hippocampus  
 binding kinetics,  $\delta$  opioid receptors, 23

- positive coupling with adenylate cyclase, non-classical serotonin receptors (guinea pig), 880
- Human immunodeficiency virus, suppression, 2',3'-dideoxynucleosides, 431
- 5-Hydroperoxyeicosatetraenoic acid, conversion into leukotriene B<sub>4</sub>, hepatocytes (rat), 256
- 5-Hydroxytryptamine, *see* Serotonin
- Hypertension, canrenone and derivatives, interaction with ouabain, 245
- Hypoxia, *tert*-butylhydroperoxide-induced oxidative injury, hepatocytes (rat), 413

## I

- Imipramine, uptake and release, transmembrane pH gradient, synaptosomes, 888
- Indoles, serotonin receptor recognition, RU 24969 analogs, 42
- Inotropes, adenylate cyclase stimulation, isobutylmethylxanthine (rat), 37
- Insecticides, pyrethroid, batrachotoxinin-A benzoate, sodium channels (rat), 54
- Insulin
  - inhibition of glucokinase by alloxan, sugar-binding site of enzyme (mouse), 395
  - receptors and epidermal growth factor, smoking-related alterations, placenta (human), 265
- Interferons, effects of double-stranded RNA in A431 cells, poly(I)-poly(C), 461
- 2-Iodo-7,8-dibromodibenzo-*p*-dioxin, *Ah* receptor-ligand binding, kinetics, equilibrium studies, 229
- Ischemia, *tert*-butylhydroperoxide-induced oxidative injury, hypoxia effect, hepatocytes (rat), 413
- Isobutylmethylxanthine, adenylate cyclase stimulation, blockade, inhibitory regulatory protein G<sub>i</sub> (rat), 37
- Isoproterenol, potency and kinetics of  $\beta$ -adrenergic receptors, potency and kinetics, neutrophils (human), 347

## K

- Kainic acid, excitatory amino acid receptors, agonist pharmacology, oocytes (*Xenopus*), 298
- Kidney
  - epithelial cells, interactions, liposome-incorporated amphotericin B, 286
  - inhibition of adenylate cyclase, serotonin-1 receptors, oxymetazoline (opposum), 1
  - metabolism and excretion of *S*-conjugates, hexachlorobutadiene (rat), 407
  - substrate specificity, phenol UDP-glucuronosyltransferase, COS-7 cells (rat, monkey), 638

## L

- Leukotriene B<sub>4</sub>, conversion of 5-hydroperoxyeicosatetraenoic acid, hepatocytes (rat), 256
- Leukotriene D<sub>4</sub>, receptors, subcellular localization, tracheal smooth muscle (sheep), 590
- Levonantradol, cannabinoid receptors, brain (rat), 605
- Ligands, *Ah* receptor binding studies, kinetics, 2-iodo-7,8-dibromodibenzo-*p*-dioxin, 229
- Lipid peroxidation, diquat-induced oxidative stress, calcium transport, liver membrane (rat), 209
- Lipolysis, subclassification of  $\beta$ -adrenergic receptors, fat cells (rat), 318
- Liposomes-incorporated amphotericin B, interactions, kidney epithelial cells, 286
- Liver
  - conversion of 5-hydroperoxyeicosatetraenoic acid, leukotriene B<sub>4</sub> (rat), 256
  - distribution and induction of cytochrome P-450, phenobarbital, 3-

- methylcholanthrene (mouse), 736
- N*-glycosidic bond conformation, nucleoside ligand binding, uridine phosphorylase (human), 104
- inhibition of ferrochelatase, *N*-alkylporphyrin regioisomers (rat), 80
- membrane calcium transport, diquat-induced oxidative stress (rat), 209
- oxygen-dependent hepatotoxicity, doxorubicin (rat), 695
- stimulation of arachidonic acid metabolism, platelet-activating factor (rat), 793
- Lysosomotropic agents, anthracycline retention, multiple drug-resistant cells, 180

## M

- Marihuana, cannabinoid receptors, brain (rat), 605
- Mephenytoin, genetically determined polymorphisms, non-human primate as model, oxidative drug metabolism, 215
- Mercury, thiol-reagents, AMPA binding, synaptic membranes (rat), 117
- N*-Methyl-D-aspartate
  - activated cationic channels, strychnine blockade, cortical neurons (rat), 98
  - receptor-ligand interactions, effects, guanine nucleotides, 111
  - receptor regulation, uncompetitive antagonist binding, brain membranes (rat), 250
- 3-Methylcholanthrene-inducible cytochrome P-450, distribution, induction sites (mouse), 736
- Methyl mercury, chain elongation, HeLa RNA polymerase II, 702
- S*-(Methylthio)-L-homocysteine, copper complex, cytidine triphosphate synthesis, L1210 cells (mouse), 401
- Methylxanthines, adenylate cyclase stimulation, isobutylmethylxanthine (rat), 37
- Microsomes
  - binding kinetics,  $\delta$  opioid receptors, 23
  - individual UDP-glucuronosyltransferase isozymes, inadequacy, perinatal glucuronidation (rat, human), 729
- Mitochondria, peripheral-type benzodiazepine ligands (rat), 272
- Monoclonal antibodies
  - calcium current modulation, BC<sub>3</sub>H1 myocytes, 518
  - distribution and induction sites, cytochrome P-450, liver (mouse), 736
  - endogenous opioid receptor components, brain (rat), 614
  - H<sub>1</sub> histamine receptor ligand recognition, SK&F 94461, 136
- Monooxygenase, two sites of azo reduction (rat), 597
- Morphine
  - fragments, structure-activity studies, 363
  - $\mu_1$  opiate binding assay, 308
- Muscle, smooth
  - tracheal, subcellular localization, leukotriene D<sub>4</sub> receptors (sheep), 590
  - vascular and tracheal relaxation, cyclic nucleotide analogs, protein kinase, 506
- Muscle cells, BC<sub>3</sub>H<sub>1</sub>, adrenergic receptor distribution regulation, 8
- Myocytes
  - BC<sub>3</sub>H<sub>1</sub>, monoclonal antibody modulation, calcium current, 518
  - cardiac sodium channels, stereospecific binding, antiarrhythmic drugs (rat), 659
  - localization of  $\beta$ -adrenergic receptor, ferritin-alprenolol probe, 444

## N

- NADH-cytochrome b<sub>5</sub> reductase, redox cycling of bleomycin-Fe(III), DNA degradation (rat), 578
- Naloxonazine,  $\mu_1$  opiate binding assay, 308
- Naphthols, substrate specificity, phenol UDP-glucuronosyltransferase, COS-7 cells (rat, monkey), 638
- Nebivolol, receptor binding profile, comparison,  $\beta$ -adrenergic blockers, 843
- Nephrotoxicity
  - 6-bromo-2,5-dihydroxy-thiophenol (rats), 15

## Nephrotoxicity—continued

- 2-bromo-(diglutathion-*S*-yl)hydroquinone (rat), 492
- segment specificity of cysteine conjugate, kidney localization (rat), 621
- Neuroblastoma cells
  - hybrid cell line, opioid receptors (mouse, hamster), 689
  - slow inactivation of single sodium channels, phenytoin, 557
- Neuronal cells, GABA<sub>A</sub> receptor turnover (chick), 354
- Neurons
  - characterization of  $\omega$ -conotoxin-binding molecule, brain synaptosomes (rat), 87
  - collicular, serotonin receptor, adenylate cyclase coupling (guinea pig), 880
  - sympathetic, caffeine-sensitive calcium stores, calcium regulation (rat), 664
- Neuropeptide Y, monoiodinated, multiple receptor site binding, brain (rat), 779
- Neutrophils, potency and kinetics,  $\beta$ -adrenergic receptors (human), 347
- Niflumate, picrate and, blockade of anion modulation, GABA/benzodiazepine receptor complex (rat), 837
- Nucleosides, ligand binding, *N*-glycosidic bond conformation, pentose moiety (human), 104

## O

- OK cells, inhibition of adenylate cyclase, serotonin-1 receptors, oxymetazoline (opposum), 1
- Oligosaccharides, adrenergic receptor distribution regulation, BC<sub>3</sub>H<sub>1</sub> muscle cells, 8
- Oocytes, excitatory amino acid receptors, agonist pharmacology (*Xenopus*), 298
- Opiates,  $\mu_1$  binding assay, 308
- Organogenesis, biotransformation of phenoxazone ethers, embryonic cytochrome P-450s (rat), 67
- Ouabain, competition at same site on Na/K-ATPase, canrenone, 6,7-dihydroxylated derivatives, 245
- Oxazolecarbamate derivatives, X-ray crystal structures, structure-activity relationship, aldose reductase inhibitors, 377
- Oxygen
  - dependent hepatotoxicity, doxorubicin (rat), 695
  - free radicals, calcium permeability, cardiac sarcoplasmic reticulum (dog), 388
- Oxymetazoline, inhibition of adenylate cyclase, serotonin-1 receptors, OK cells (opposum), 1

## P

- Pancreas, calcium mobilization, arachidonic acid release, tetrahydrocannabinol (rat), 543
- Parathyroid gland, dopamine D<sub>1</sub> receptors (calf), 29
- Peptide YY, monoiodinated, multiple receptor site binding, brain (rat), 779
- Pertussis toxin
  - autoreceptor-mediated inhibition, dopamine synthesis, striatum (rat), 715
  - binding kinetics,  $\delta$  opioid receptors, 23
  - treated fibroblasts, enhanced sensitivity, bradykinin, 279
- pH, transmembrane gradient, imipramine and haloperidol uptake, synaptosomes, 888
- Phencycline-like drugs,  $\sigma$  drugs and, receptor site topographies, 863
- Phenobarbital
  - induced rat, 1,3-(2-chloroethyl)-1-nitrosourea, acetaminophen toxicity, 584
  - inducible cytochrome P-450, distribution, induction sites (mouse), 736
- Phenolic compounds, UDP-glucuronosyltransferase, substrate specificity, COS-7 cells (rat, monkey), 638
- Phenol sulfotransferase, monoamine-sulfating form of, characterization, platelets, 194
- Phenylbutazone, prostaglandin hydroperoxidase-dependent oxidation,

inhibition, prostaglandin cyclooxygenase, 186

- Phenyl-pyrone, computer-automated structure evaluation, flavonoids, 210
- Phenytoin, slow inactivation of single sodium channels, neuroblastoma cells, 557
- Phosphoinositide, batrachotoxin-elicited sodium flux, local anesthetics, cerebral cortical synaptoneuroosomes (guinea pig), 707
- Phosphorylation
  - $\gamma$ -aminobutyric acid<sub>A</sub> receptor function, whole-cell recording (chick), 719
  - light-dependent rhodopsin, inhibition by transducin, 452
- Picrate, niflumate and, blockade of anion modulation, GABA/benzodiazepine receptor complex (rat), 837
- Pituitary cells, iodination of somatostatin, super high affinity ligand (rat), 651
- Placenta, smoking-related alterations, epidermal growth factor, insulin receptors (human), 265
- Platelet-activating factor
  - stimulation of arachidonic acid metabolism, liver cells (rat), 793
  - tritiated, high affinity specific binding (dog), 145
- Platelets, monoamine-sulfating form of phenol sulfotransferase, characterization, 194
- Polyclonal antibodies, H<sub>1</sub> histamine receptor ligand recognition, SK&F 94461, 136
- Polymorphisms, genetically determined, non-human primate as model, oxidative drug metabolism, 215
- Porfirimycin, flavoenzyme-activated, metabolites, DNA adduct formation, 223
- Porphyria, inhibition of hepatic ferrochelatase, *N*-alkylporphyrin regioisomers (rat), 80
- Porphyrin, interactions, peripheral-type benzodiazepine receptors (rat, rabbit), 800
- Potassium, regulation of  $\alpha$ -bungarotoxin sites, nicotinic receptor ligands, chromaffin cells, 549
- Potassium channels
  - block by clofilium and its tertiary analogs, heart (guinea pig), 60
  - blockade by dendrotoxins, brain synaptosomes (rat), 152
- Progesterone, substrate specificity, cytochrome P-450III<sub>A1</sub> (rat), 628
- Prostaglandin H synthase hydroperoxidase, -dependent oxidation, phenylbutazone, inhibition of prostaglandin cyclooxygenase, 186
- Prostaglandins, enhanced sensitivity to bradykinin, pertussis toxin-treated fibroblasts, 279
- Protein kinase
  - cGMP-dependent, vascular and tracheal smooth muscle relaxation, 506
  - smoking-related placental alterations, epidermal growth factor, insulin receptors (human), 265
- Protein kinase C, activators,  $\alpha_1$ -adrenergic receptor internalization (hamster), 340
- Pyrethroid insecticides, batrachotoxinin-A benzoate binding site, sodium channels (rat), 54

## Q

- Quinones, glutathione addition to 1,4-benzoquinone, sequential oxidation, toxicity correlation, 829
- Quisqualate, excitatory amino acid receptors, agonist pharmacology, oocytes (*Xenopus*), 298

## R

- Radioligands
  - agonist interactions, atrial A<sub>1</sub> adenosine receptors (pig), 334
  - high affinity acylating antagonists, A<sub>1</sub> adenosine receptor (rat), 724
- Receptors
  - acetylcholine
    - bungarotoxin binding sites (*Torpedo*), 643
    - gating, forskolin, 427
  - adenosine, adenylate cyclase stimulation, isobutylmethylxanthine

- (rat), 37  
adenosine A<sub>1</sub>  
agonist radioligand interactions (pig), 334  
binding subunit identification (rat), 724  
adrenergic, *see* Adrenoceptors  
**Ah**  
competitive binding assay, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 682  
ligand binding studies, 2-iodo-7,8-dibromodibenzo-*p*-dioxin, 229  
aldose reductase inhibitors, drug-receptor interactions, artificial intelligence approach, 852  
benzodiazepine  
anion modulation blockade, picrate and niflumate (rat), 837  
GABA<sub>A</sub> receptor turnover, neuronal cells (chick), 354  
*in vivo* binding,  $\beta$ -carboline (mouse), 124  
peripheral-type, porphyrin interactions (rat, rabbit), 800  
cannabinoid, brain (rat), 605  
dopamine D<sub>1</sub>, parathyroid gland (calf), 29  
dopamine D<sub>2</sub>, deglycosylation (dog, pig), 91  
excitatory amino acid, agonist pharmacology, oocytes (*Xenopus*), 298  
GABA<sub>A</sub>  
benzodiazepine interactions, ciliary ganglion nerves (chick), 129  
phosphorylation, whole-cell recording (chick), 719  
glutamate, AMPA binding to synaptic membranes, thiol-reagents (rat), 117  
histamine H<sub>1</sub>, antibody recognition, SK&F 94461, 136  
5-HT<sub>1</sub>, adenylate cyclase coupling, central nervous system (guinea pig), 880  
insulin, smoking-related alterations, placenta (human), 265  
leukotriene D<sub>4</sub>, subcellular localization, tracheal smooth muscle (sheep), 590  
muscarinic  
antibodies, brain and heart (rat), 327  
coupling to electrical responses, A9 L cells, 421  
muscarinic acetylcholine, adenylate cyclase inhibition, agonist efficacy distinction (rat), 769  
neboivolol, profile of, compared to  $\beta$ -adrenergic blockers, 843  
nicotinic,  $\alpha$ -bungarotoxin sites, chromaffin cells, 549  
NMDA  
channel activation, hippocampal membranes (rat), 250  
ligand interactions, guanine nucleotide effects, 111  
neuroblastoma-brain hybrid cell line (mouse, hamster), 689  
strychnine blockade, cortical neurons (rat), 98  
opiate,  $\mu_1$  binding assay, 308  
opioid  
monoclonal antibodies, brain (rat), 614  
neuroblastoma-brain hybrid cell line (mouse, hamster), 689  
tight coupling to G proteins, NG108-15 cell membranes, 744  
opioid  $\delta$   
binding kinetics, 23  
iodinated azido-ligand, 436  
phencyclidine, neuroblastoma-brain hybrid cell line (mouse, hamster), 689  
phencycline-like and  $\sigma$  drugs, site topographies, 863  
platelet-activating factor, high affinity binding (dog), 145  
serotonin, recognition, RU 24969, 42  
serotonin-1, adenylate cyclase inhibition, oxymetazoline (oppossum), 1  
sigma, neuroblastoma-brain hybrid cell line (mouse, hamster), 689  
somatostatin, iodination, super high affinity ligand (rat), 651  
Rhodopsin kinase, light-dependent phosphorylation, inhibition, transducin, 452  
Ribonucleotide reductase, 2-halogenated deoxyadenosine analogs, mechanism of action, 485  
RNA, double-stranded, poly(I)-poly(C), A431 cells, 461  
RNA polymerase II, methyl mercury, chain elongation, HeLa cells, 702  
Ro15-1788, *in vivo* binding,  $\beta$ -carboline (mouse), 124  
RP 59227, high affinity specific binding sites, tritiated platelet-activating factor (dog), 145  
RU 24969 analogs, recognition at serotonin sites, 42  
Ryanodine, caffeine-sensitive calcium stores, regulation, sympathetic neurons (rat), 664
- S**
- Saccharomyces cerevisiae*, cytotoxic effects of camptothecin, necessity of DNA topoisomerase I, 755  
Salicylate, high affinity binding sites, human serum albumin, 160  
Sarcoplasmic reticulum, cardiac, oxygen free radicals, calcium permeability (dog), 388  
SCH-23390, dopamine D<sub>1</sub> receptors, parathyroid gland (calf), 29  
Secretagogue-evoked phosphoinositide breakdown, arachidonic acid release, tetrahydrocannabinol (rat), 543  
Serotonin  
binding sites in brain, G protein reconstitution (bovine), 527  
novel binding site in brain membranes, 4-bromo-2,5-dimethoxyamphetamine (rat), 537  
receptor recognition, RU 24969 analogs, 42  
receptors in OK cells, adenylate cyclase inhibition, oxymetazoline (oppossum), 1  
SK&F 94461, monoclonal and polyclonal antibody recognition, 136  
Sodium  
binding kinetics,  $\delta$  opioid receptors, 23  
flux in cerebral cortical synaptoneurosomes, local anesthetics (guinea pig), 707  
Sodium channels  
batrachotoxin-A benzoate binding site, pyrethroid insecticides (rat), 54  
cardiac, stereospecific binding, antiarrhythmic drugs (rat), 659  
slow inactivation, phenytoin, neuroblastoma cells, 557  
Sodium-potassium-ATPase, ouabain competition, canrenone, 6,7-dihydroxylated derivatives, 245  
Somatostatin, iodination, high affinity ligand, pituitary cells (rat), 651  
Striatum  
dopamine synthesis, pertussis toxin, autoreceptor-mediated inhibition (rat), 715  
muscarinic acetylcholine receptors, distinction of, agonist efficacy (rat), 769  
Strychnine  
anion regulation of binding, glycine-gated chloride channels, 806  
voltage-dependent block of NMDA-activated channels, cortical neurons (rat), 98  
Substrate  
phenol UDP-glucuronosyltransferase, COS-7 cells (rat, monkey), 638  
specificity of cytochrome P-450III<sub>A1</sub> (rat), 628  
Sulphydryl, inhibition of cellular DNA synthesis, selenite, 573  
Sulphydryl reagents, thiol-reagents, AMPA binding, synaptic membranes (rat), 117  
Sulmazole, function of G proteins, affect, GTP turnover (rat), 761  
Sympathetic neurons, regulation of intracellular calcium, caffeine-sensitive calcium stores (rat), 664  
Synapse, binding kinetics,  $\delta$  opioid receptors, 23  
Synaptoneurosomes, cerebral cortical, sodium flux, local anesthetics (guinea pig), 707  
Synaptosomes  
brain  
characterization,  $\omega$ -conotoxin-binding molecule (rat), 87  
dendrotoxin blockade, potassium channels (rat), 152  
imipramine and haloperidol uptake and release, role, transmembrane pH gradient, 888
- T**
- T cells, activation of calcium channels, Bay K 8644, 239  
Testicular cells, 1,2-dibromo-3-chloropropane activation (rat), 74  
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, competitive binding assay, *Ah* receptor, 682

Tetrahydrocannabinol  
 cannabinoid receptors, brain (rat), 605  
 increase in arachidonic acid levels, cerebral cortex slices (guinea pig), 823  
 -induced arachidonic acid release, calcium mobilization, exocrine pancreas (rat), 543  
*N*-(1-[Thienyl]cyclohexyl)piperidine, NMDA receptor regulation, uncompetitive antagonist binding, brain membranes (rat), 250  
 Thiol-reagents, AMPA binding, synaptic membranes (rat), 117  
 Thymidylate synthase  
 5-fluoro-2'-deoxyuridine response, colonic tumor cell lines (human), 474  
 naturally occurring variation, 5-fluoro-2'-deoxyuridine, colonic tumor (human), 480  
 Topoisomerase I, cytotoxic effects of camptothecin, 755  
 Topoisomerase II, mechanism of inhibition, DNA binding, epipodophyllotoxins and *N*-acyl anthracyclines, 467  
 Transducin, inhibition of light-dependent rhodopsin phosphorylation,  $\beta\gamma$  subunit interaction, 452  
 Tubulin, combretastatin interactions, natural and synthetic analogs, 200

## U

UDP-glucuronosyltransferase  
 individual isozymes in liver microsomes, inadequacy, perinatal glu-

curonidation (rat, human), 729  
 substrate specificity, COS-7 cells (rat, monkey), 638  
 Uridine phosphorylase, *N*-glycosidic bond conformation, pentose moiety, nucleoside ligand binding (human), 104

## V

Verapamil  
 1,4-dihydropyridine binding, allosteric modulation, cardiac cells (rat), 172  
 lysosomotropic agents, antracycline retention, multiple drug-resistant cells, 180

## W

Warfarin, high affinity binding sites, human serum albumin, 160

## X

Xanthine amine cogener,  $A_1$  adenosine receptor, high affinity acylating antagonists (rat), 724  
 Xanthine oxidase, oxygen free radicals, calcium permeability, cardiac sarcoplasmic reticulum (dog), 388  
 X-ray, crystal structures of oxazolocarbamate derivatives, structure-activity relationship, aldose reductase inhibitors, 377

**Copyright © 1988 by the American Society for  
Pharmacology and Experimental Therapeutics**

## INSTRUCTIONS TO AUTHORS

*Molecular Pharmacology* will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

**Page charges.** Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

**Submission of manuscript.** Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

**Accelerated Communications.** In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

*Organization and style of manuscripts.* The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baucke, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brien. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

*Tables.* These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

*Figures.* These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used ( $\times$ ,  $\circ$ ,  $\bullet$ ,  $\square$ ,  $\blacksquare$ ,  $\triangle$ ,  $\blacktriangle$ ,  $\odot$ ). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

*Page proof.* Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

*Reprints and page charges.* An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.



## INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

*Correspondence concerning business matters* should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202 U.S.A.

*Correspondence regarding editorial matters* should be addressed to the Editor, Dr. William A. Catterall, Department of Pharmacology, SJ-30, University of Washington, Seattle, WA 98195.

*Annual Subscription Rates*—U. S. A. AND POSSESSIONS: personal, \$75.00; institutional, \$165.00, single copy, \$16.00. FOREIGN: personal, \$90.00; institutional, \$180.00; single copy, \$19.00. JAPAN: personal, \$123.00; institutional, \$213.00 (includes air freight). (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost.

Japanese Yen price is available from our sole agent: USACO Corporation, 13-12 Shimbashi 1-Chome, Minato-Ku, Tokyo 105, Japan, telephone 03-502-6471.

*Change of address:* Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

*New subscriptions and renewals* are entered to begin with the January or July issue.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

*Reprints* of individual articles are available *only* from authors.

*Microfilm.* For availability, inquire of Williams & Wilkins.

**Williams & Wilkins, Baltimore, MD. 21202 U. S. A.**